Perspective Therapeutics to Participate in Upcoming February Investor Conferences
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on advanced cancer treatments, has announced its participation in two major investor conferences in February 2025.
The company will attend Oppenheimer's 35th Annual Healthcare Life Sciences Conference, featuring a virtual fireside chat on Wednesday, February 12, 2025, from 2:00 p.m. to 2:30 p.m. ET. Additionally, they will participate in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York, NY on Friday, February 28, 2025.
Senior leadership team members will be available for one-on-one meetings with investors at both events. Webcasts will be accessible live and archived for 90 days through the Investors page on Perspective's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda radioterapeutica focalizzata su trattamenti avanzati per il cancro, ha annunciato la sua partecipazione a due importanti conferenze per investitori a febbraio 2025.
L'azienda parteciperà alla 35ª Conferenza Annuale sulle Scienze della Vita di Oppenheimer, che includerà una chat virtuale mercoledì 12 febbraio 2025, dalle 14:00 alle 14:30 ET. Inoltre, parteciperanno alla Conferenza per Investitori in Oncologia di Precisione e Radioterapia di B. Riley Securities a New York, NY, venerdì 28 febbraio 2025.
I membri del team dirigenziale saranno disponibili per incontri individuali con gli investitori durante entrambi gli eventi. I webcast saranno accessibili in diretta e archiviati per 90 giorni attraverso la pagina dedicata agli investitori sul sito di Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX), una empresa de radiofármacos centrada en tratamientos avanzados para el cáncer, ha anunciado su participación en dos importantes conferencias de inversores en febrero de 2025.
La empresa asistirá a la 35ª Conferencia Anual de Ciencias de la Vida de Oppenheimer, que contará con una charla virtual el miércoles 12 de febrero de 2025, de 2:00 p.m. a 2:30 p.m. ET. Además, participarán en la Conferencia para Inversores de Oncología de Precisión y Radiofármacos de B. Riley Securities en Nueva York, NY, el viernes 28 de febrero de 2025.
Los miembros del equipo directivo estarán disponibles para reuniones individuales con inversores en ambos eventos. Las transmisiones en vivo estarán disponibles y archivadas durante 90 días a través de la página de inversores en el sitio web de Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX), 고급 암 치료에 중점을 둔 방사성 약물 회사가 2025년 2월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 Oppenheimer 제35회 연례 생명 과학 회의에 참석할 예정이며, 2025년 2월 12일 수요일 오후 2시부터 2시 30분(ET)까지 가상 대화도 있을 예정입니다. 또한, 그들은 B. Riley Securities 정밀 종양학 및 방사선 투자자 회의에 참가할 예정입니다. 뉴욕, NY에서 2025년 2월 28일 금요일에 열립니다.
고위 관료팀 구성원들은 두 행사에서 투자자와의 일대일 회의가 가능할 것입니다. 웹캐스트는 라이브로 접근할 수 있으며, Perspective 웹사이트의 투자자 페이지를 통해 90일 동안 아카이브됩니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une entreprise de radiopharmaceutiques spécialisée dans les traitements avancés contre le cancer, a annoncé sa participation à deux grandes conférences pour investisseurs en février 2025.
L'entreprise assistera à la 35ème Conférence Annuelle sur la Santé de Oppenheimer, qui comprendra une discussion virtuelle le mercredi 12 février 2025, de 14h00 à 14h30 ET. De plus, elle participera à la Conférence des Investisseurs en Oncologie de Précision et Radiopharma de B. Riley Securities à New York, NY, le vendredi 28 février 2025.
Les membres de l'équipe de direction seront disponibles pour des réunions individuelles avec les investisseurs lors des deux événements. Les webcasts seront accessibles en direct et archivés pendant 90 jours sur la page des investisseurs du site de Perspective.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Radiopharmazieunternehmen, das sich auf fortschrittliche Krebsbehandlungen spezialisiert hat, hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im Februar 2025 bekannt gegeben.
Das Unternehmen wird an der 35. jährlichen Healthcare Life Sciences Conference von Oppenheimer teilnehmen, die am Mittwoch, den 12. Februar 2025, von 14:00 bis 14:30 Uhr ET eine virtuelle Diskussion umfasst. Darüber hinaus werden sie an der B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York, NY, am Freitag, den 28. Februar 2025, teilnehmen.
Die Mitglieder des Senior Leadership Teams stehen bei beiden Veranstaltungen für Einzelgespräche mit Investoren zur Verfügung. Live-Übertragungen werden verfügbar sein und 90 Tage lang über die Investoren-Seite der Website von Perspective archiviert.
- None.
- None.
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
Oppenheimer's 35th Annual Healthcare Life Sciences Conference – Fireside Chat
Date: Wednesday, February 12, 2025
Time: 2:00 p.m. - 2:30 p.m. ET
Location: Virtual
B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Date: Friday, February 28, 2025
Location: New York, NY
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moeities which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moeities provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com
FAQ
When is Perspective Therapeutics (CATX) presenting at the Oppenheimer Healthcare Conference in 2025?
Where can investors watch CATX's February 2025 conference presentations?
Which investor conferences is CATX attending in February 2025?
Will CATX management be available for one-on-one meetings at the February 2025 conferences?
